Locations:
Search IconSearch
October 3, 2018/Cancer

First Prostate Surgery Performed in U.S. Using Single Port SP Robot

Surgeons completed radical prostatectomy using new-generation robot

SP-Port-Robot-1-650×450

Cleveland Clinic is the first hospital in the country to successfully perform surgeries using the Single Port SP Robot, which inserts all surgical instruments through one small abdominal incision, improving surgical outcomes and allowing quicker patient recovery.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

New generation robot used in 3 surgeries

On Sept. 28, Cleveland Clinic surgeons used the SP Robot to perform three surgeries — two surgeries to remove cancerous prostates and one surgery to remove an enlarged prostate blocking the urinary system through the bladder.

Jihad Kaouk, MD, Director of the Center for Robotic and Image Guided Surgery in the Glickman Urologic and Kidney Institute, was the first to perform and publish on robotic single-port surgery in 2008 using standard robotic systems and coining the phrase R-LESS (robotic laparoendoscopic single site surgery).

After completing and publishing the first ever clinical use for the SP robot in Europe, Dr. Kaouk and his team also performed last week’s radical prostatectomies and transvesical simple prostatectomy at Cleveland Clinic. The new purpose-built robotic SP system will allow the single port approach to be more feasible.

Making the previously impossible possible

“We anticipate that this new generation of robots will allow for new and different routes of surgeries that haven’t previously been possible,” Dr. Kaouk says. “For example, we can now go through a patient’s perineum instead of their belly to perform prostate surgery and avoid touching the bowel, or work through the retroperitoneal space to perform kidney surgery without entering the abdomen, allowing for quicker recovery time.”

Currently, the SP Robot is only FDA-approved for urologic surgeries, with plans to expand to ENT and colorectal surgeries in the near future.

“We are proud to offer this surgical approach and be on the forefront of surgical innovation,” adds Mark A. Taylor, MD, Chairman of Surgical Operations at Cleveland Clinic.

Advertisement

Dr. Kaouk worked with the Intuitive Inc. team of engineers to test and improve the new robotic system. Dr. Kaouk is a paid consultant, speaker or member of the advisory committee for Endocare, Inc. and Intuitive Surgical, Inc.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad